How Can a Multidisciplinary Approach Improve Prognosis of Soft-Tissue Sarcomas of Extremities?
Journal
International journal of surgical oncology
ISSN: 2090-1410
Titre abrégé: Int J Surg Oncol
Pays: United States
ID NLM: 101566285
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
08
2020
revised:
21
02
2021
accepted:
10
03
2021
entrez:
9
4
2021
pubmed:
10
4
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Soft-tissue sarcomas are malignant tumors that require good management within specialized centers. Our study aims to assess the benefit of handling these kinds of tumors using the Multidisciplinary Meeting (MDM) approach. The current paper details this approach through a prospective study that has lasted for 42 months in the HASSAN II University Hospital Center, Fez, Morocco. During this research work, 116 cases were selected with an average age of 53 years. In 95.7% of the cases, it was found that the lower limb was the most frequent tumor type (78.4%). Also, ninety-two (92) patients (79.3%) have had a prior biopsy. Ninety-nine (99) patients (85.3%) have received a magnetic resonance imaging scan (MRI) before surgery. Sixty-three (63) patients were operated on, including R0 resection used for 37 patients, R1 used for 21 patients, and R2 used for five patients. As a result, liposarcomas were the most frequent type (30.1%), followed by synovial sarcomas (14.6%), leiomyosarcomas (9.5%), ewing sarcoma (8.6), and undifferentiated pleomorphic sarcomas (7.7%). In addition, neoadjuvant chemotherapy was used for 36 patients. The other 22 patients received adjuvant chemotherapy and/or radiotherapy. The overall survival rate was 60.56 months, which proves a significant improvement, thanks to the multidisciplinary meeting approach.
Identifiants
pubmed: 33833875
doi: 10.1155/2021/8871557
pmc: PMC8012127
doi:
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8871557Informations de copyright
Copyright © 2021 Asmae Mazti et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Arch Surg. 1999 Aug;134(8):856-61; discussion 861-2
pubmed: 10443809
Acta Orthop Scand. 1994 Feb;65(1):47-50
pubmed: 8154283
Pan Afr Med J. 2019 Jul 15;33:207
pubmed: 31692722
Ann Chir Plast Esthet. 2017 Feb;62(1):15-22
pubmed: 27777135
Br J Surg. 1997 Dec;84(12):1692-6
pubmed: 9448617
Eur J Surg Oncol. 2019 Jan;45(1):19-21
pubmed: 29395437
Eur J Gynaecol Oncol. 1998;19(1):64-8
pubmed: 9476063
Eur J Surg Oncol. 2010 Jul;36(7):684-90
pubmed: 20542404
Eur J Surg Oncol. 2002 Mar;28(2):153-64
pubmed: 11884051
Ann Oncol. 2017 Nov 1;28(11):2852-2859
pubmed: 29117335
Eur J Surg Oncol. 2006 Dec;32(10):1242-8
pubmed: 16793237
Ann Oncol. 2010 May;21 Suppl 5:v198-203
pubmed: 20555081
J Natl Med Assoc. 2007 Jan;99(1):88-93
pubmed: 17304972
Ann Surg Oncol. 2012 Sep;19(9):2981-91
pubmed: 22476756
Bull Cancer. 2004 Oct;91(10):799-804
pubmed: 15556881
Cancer. 1981 Mar 1;47(5):1005-22
pubmed: 7226034
Eur J Cancer. 1996 Jun;32A(7):1198-204
pubmed: 8758253
Ann Oncol. 2014 Sep;25 Suppl 3:iii102-12
pubmed: 25210080
Ann Oncol. 2004 Feb;15(2):307-15
pubmed: 14760127
Lancet Oncol. 2016 Feb;17(2):e62-e69
pubmed: 26868355
Eur J Surg Oncol. 2019 Jan;45(1):31-39
pubmed: 28985973
Acta Orthop Scand. 1983 Dec;54(6):929-34
pubmed: 6670522
J Bone Joint Surg Am. 1994 Aug;76(8):1167-73
pubmed: 8056797